Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Non Operating Income (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Non Operating Income for 8 consecutive years, with $1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income rose 256.49% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $1.7 million, up 742.99%, while the annual FY2025 figure was -$690000.0, 131.94% down from the prior year.
  • Non Operating Income hit $1.4 million in Q1 2026 for Crescent Biopharma, up from -$285000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.4 million in Q1 2026 and bottomed at -$924000.0 in Q1 2025.
  • Average Non Operating Income over 3 years is $268310.3, with a median of $512194.0 recorded in 2023.
  • On a YoY basis, Non Operating Income climbed as much as 256.49% in 2026 and fell as far as 256.49% in 2026.
  • Crescent Biopharma's Non Operating Income stood at $512194.0 in 2023, then plummeted by 155.64% to -$285000.0 in 2025, then surged by 607.37% to $1.4 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $1.4 million, -$285000.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.